BION Active Seating for Pressure Ulcer Prevention
Primary Purpose
Pressure Ulcer
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
BION
Sponsored by
About this trial
This is an interventional treatment trial for Pressure Ulcer focused on measuring Neuromuscular stimulator, Pressure ulcer prevention
Eligibility Criteria
Inclusion Criteria:
- Subject has had a spinal cord injury and has bilateral lower limb paralysis.
- Subject cannot contract his/her gluteus muscle voluntarily.
- Subject is between 18 and 70 years old.
- Subject sits in a wheelchair for at least 5 hours per day.
- Attending physician considers the subject in general good health (other than SCI and PU wound).
- Subject has one or more PUs of Stage III or IV (according to National Pressure Ulcer Advisory Panel Staging1).
- Subject is having a musculocutaneous (not cutaneous or fasciocutaneous) gluteal rotation flap surgery for PU treatment in which the inferior gluteal pedicle and sciatic nerve will be exposed but not damaged or sacrificed in any way (for any PU wound(s)).
- Subject is mentally capable of understanding the goals and the application of therapy.
- Subject is able to apply the therapy (with or without help) once discharged from Rancho Los Amigos.
- Subject is willing and capable of giving informed consent.
- Subject is willing and capable of traveling to testing center at the schedules.
Exclusion Criteria:
- Subject has a positive pregnancy test, is nursing / lactating, or is planning on becoming pregnant or is unwilling to not become pregnant in the next 12 months.
- Subject has an electronic implant (e.g. cardiac pacemaker, etc.).
Subject has any condition associated with a wound healing abnormality (e.g.: connective tissue disorder, immune disorder, diabetes, clinical obesity).
IDE application: BION Active Seating for Pressure Ulcer Prevention Page 65
- Subject is malnourished.
- The attending physician has concerns about the healing of this subject (e.g.: heavy smoking, excessive and/or poorly-managed incontinence).
- Subject has concurrent concomitant condition affecting the buttock/pelvic area, including other pressure wound not corrected by the flap surgery.
- Subject suffers from claustrophobia or fear of MRI, or has any contraindication to MRI (e.g. metal implants, pacemaker, etc. not suited to MRI).
- Subject has damage to the inferior or superior gluteal neurovascular pedicles.
- Subject is / plans to participate in another investigational study that may affect the healing of PUs or prevent their occurrence/recurrence.
- Subject is using medications / undergoing procedures that will interfere with NMES effecting muscle contraction (e.g. treatments for spasticity and / or spasms, such as: neurotomies, tenotomies, myotomies, and rhizotomies; as well as tranquilizers and muscle relaxant / paralyzing agents such as Baclofen (Lioresal®), Dantrolene (Dantrium®) and Botulinum Toxin Type A (Botox®)).
- Subjects whose ulcer extends more than 2.25" deep to the projected surface contour of the buttock when the patient is in a prone position (measured perpendicular to the base of the PU, from the deepest point of the PU to the level of the highest point of the buttock surface, when prone)
- Subject's wheelchair and the BION system have been tested for interference of either with the other's operation, and either does not operate normally when used together, and this cannot be resolved with an available alternate wheelchair.
Sites / Locations
- Rancho Los Amigos National Rehabilitation Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Rx Group
Control Group
Arm Description
BION Therapy Group
control group
Outcomes
Primary Outcome Measures
Clinical assessment of movement and shifting of weight during BAS. Record shifts in pressure distribution over seated pressure points during NMES.
Secondary Outcome Measures
Clinical Examination of Braden Scale assessment,Reperfusion time,Recurrence of wounds and Body Mass Index
Full Information
NCT ID
NCT00628602
First Posted
February 25, 2008
Last Updated
June 1, 2015
Sponsor
University of Southern California
1. Study Identification
Unique Protocol Identification Number
NCT00628602
Brief Title
BION Active Seating for Pressure Ulcer Prevention
Official Title
BION Active Seating for Pressure Ulcer Prevention
Study Type
Interventional
2. Study Status
Record Verification Date
June 2015
Overall Recruitment Status
Completed
Study Start Date
November 2007 (undefined)
Primary Completion Date
December 2008 (Actual)
Study Completion Date
December 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Southern California
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Pressure ulcers (PUs) are a debilitating pathology resulting from pressure and shear in the soft tissues of immobilized patients. In studies to date, BION neuromuscular stimulation has been demonstrated to activate strong muscle contractions and to produce skeletal motion, with associated increases in muscle bulk (hypertrophy), strength, and metabolic capacity, hence counteracting the 3 major etiological factors in PU development (immobility, soft-tissue atrophy and hypoxia).
This study intends to use neuromuscular stimulation to both shift paralyzed subjects' weight and build up gluteal muscle volume, in order to prevent recurrence of pressure ulcers. We will implant BIONs alongside the already exposed inferior gluteal and sciatic nerves in patients who are undergoing gluteal rotation flap surgery for PU reconstruction. The gluteal rotation flap is a common reconstructive technique for treating PUs by bringing healthy muscle and skin in to repair the deficient area, and to provide healthy tissue covering over bony prominences. The implanted BIONs will enable us subsequently to stimulate the gluteus maximus and hip extensor muscles. Outcome measures will include tissue health variables (measured by clinical assessment, X-Rays, MRI and Sesta-MIBI SPECT perfusion scans), pressure redistribution (measured by an array of pressure sensors), and recurrence rates over 12 months.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pressure Ulcer
Keywords
Neuromuscular stimulator, Pressure ulcer prevention
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
3 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Rx Group
Arm Type
Experimental
Arm Description
BION Therapy Group
Arm Title
Control Group
Arm Type
Placebo Comparator
Arm Description
control group
Intervention Type
Device
Intervention Name(s)
BION
Intervention Description
30 patients operated will be randomized into 2 equal groups, a BION Therapy Group ("Rx group") and a Control Group ("Control group").
Primary Outcome Measure Information:
Title
Clinical assessment of movement and shifting of weight during BAS. Record shifts in pressure distribution over seated pressure points during NMES.
Time Frame
upon discharge and at the 12-week, 20-week, 36-week and 52-week outpatient follow-up visits.
Secondary Outcome Measure Information:
Title
Clinical Examination of Braden Scale assessment,Reperfusion time,Recurrence of wounds and Body Mass Index
Time Frame
preoperation, upon removal of sutures, upon discharge, and at the 12-week, 20-week, 36-week and 52-week outpatient follow-up visits.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject has had a spinal cord injury and has bilateral lower limb paralysis.
Subject cannot contract his/her gluteus muscle voluntarily.
Subject is between 18 and 70 years old.
Subject sits in a wheelchair for at least 5 hours per day.
Attending physician considers the subject in general good health (other than SCI and PU wound).
Subject has one or more PUs of Stage III or IV (according to National Pressure Ulcer Advisory Panel Staging1).
Subject is having a musculocutaneous (not cutaneous or fasciocutaneous) gluteal rotation flap surgery for PU treatment in which the inferior gluteal pedicle and sciatic nerve will be exposed but not damaged or sacrificed in any way (for any PU wound(s)).
Subject is mentally capable of understanding the goals and the application of therapy.
Subject is able to apply the therapy (with or without help) once discharged from Rancho Los Amigos.
Subject is willing and capable of giving informed consent.
Subject is willing and capable of traveling to testing center at the schedules.
Exclusion Criteria:
Subject has a positive pregnancy test, is nursing / lactating, or is planning on becoming pregnant or is unwilling to not become pregnant in the next 12 months.
Subject has an electronic implant (e.g. cardiac pacemaker, etc.).
Subject has any condition associated with a wound healing abnormality (e.g.: connective tissue disorder, immune disorder, diabetes, clinical obesity).
IDE application: BION Active Seating for Pressure Ulcer Prevention Page 65
Subject is malnourished.
The attending physician has concerns about the healing of this subject (e.g.: heavy smoking, excessive and/or poorly-managed incontinence).
Subject has concurrent concomitant condition affecting the buttock/pelvic area, including other pressure wound not corrected by the flap surgery.
Subject suffers from claustrophobia or fear of MRI, or has any contraindication to MRI (e.g. metal implants, pacemaker, etc. not suited to MRI).
Subject has damage to the inferior or superior gluteal neurovascular pedicles.
Subject is / plans to participate in another investigational study that may affect the healing of PUs or prevent their occurrence/recurrence.
Subject is using medications / undergoing procedures that will interfere with NMES effecting muscle contraction (e.g. treatments for spasticity and / or spasms, such as: neurotomies, tenotomies, myotomies, and rhizotomies; as well as tranquilizers and muscle relaxant / paralyzing agents such as Baclofen (Lioresal®), Dantrolene (Dantrium®) and Botulinum Toxin Type A (Botox®)).
Subjects whose ulcer extends more than 2.25" deep to the projected surface contour of the buttock when the patient is in a prone position (measured perpendicular to the base of the PU, from the deepest point of the PU to the level of the highest point of the buttock surface, when prone)
Subject's wheelchair and the BION system have been tested for interference of either with the other's operation, and either does not operate normally when used together, and this cannot be resolved with an available alternate wheelchair.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lucinda Baker, Ph.D.
Organizational Affiliation
University of Southern California
Official's Role
Principal Investigator
Facility Information:
Facility Name
Rancho Los Amigos National Rehabilitation Center
City
Downey
State/Province
California
ZIP/Postal Code
90242
Country
United States
12. IPD Sharing Statement
Learn more about this trial
BION Active Seating for Pressure Ulcer Prevention
We'll reach out to this number within 24 hrs